Kornimate/medical-research-clean huggingface dataset:
study on optimizing the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Conditions: Acute Myeloid Leukemia (AML)

Summary: a multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

this study is a randomized controlled, prospective clinical trial, with the leading unit being the first hospital of jilin university. it aims to screen patients with a suboptimal response to chemotherapy based on early peripheral blood minimal residual disease (mrd) levels, and explore the efficacy and safety of adding venetoclax. a total of 70 subjects are expected to be enrolled, with 35 subjects each in the experimental group and the control group. the study will collect data on subjects' demographics, other baseline characteristics, medication usage, prognosis, etc. statistical analysis will be performed on the collected data to compare efficacy indicators.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed aml patients confirmed by bone marrow morphology and immunophenotyping. 2. complete micm (morphology, immunophenotyping, cytogenetics, molecular genetics) work-up. 3. age ≥ 18 years. 4. eastern cooperative oncology group (ecog) performance status of 0-2. 5. day 6 peripheral blood blast percentage (d6pbbp) ≥ 1%. 6. renal function with creatinine clearance ≥ 50 ml/min (calculated using the cockcroft-gault formula or measured by 24-hour urine collection). 7. liver function with aspartate aminotransferase (ast) ≤ 2.5 × uln\*; alanine aminotransferase (alt) ≤ 2.5 × uln\*; total bilirubin ≤ 1.5 × uln\* (\*unless considered due to leukemia infiltration). 8. patients deemed suitable to receive da/ia therapy by the investigator. 9. signed informed consent form. - exclusion criteria: 1. acute promyelocytic leukemia (apl). 2. mixed phenotype acute leukemia (mpal). 3. aml patients with known central nervous system (cns) involvement. 4. presence of extramedullary disease (emd). 5. significant hepatic or renal dysfunction exceeding the inclusion criteria limits. 6. severe cardiac disease, including congestive heart failure, myocardial infarction, or cardiac dysfunction. 7. concurrent active malignancy of other organ systems (patients with a history of cured malignancy may be eligible). 8. active tuberculosis or hiv-positive patients. 9. concurrent other hematological disorders. 10. pregnant or lactating women. 11. inability to comprehend or comply with the study protocol. 12. hypersensitivity to any component of the drugs involved in the protocol. 13. inability to take oral medication or patients with malabsorption syndrome. 14. uncontrolled systemic infection. 15. prior venetoclax treatment and/or current participation in any other study involving investigational agents.
predictive factors for medullary thyroid cancer aggressiveness

Conditions: Medullary Thyroid Cancer

Summary: this study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival.

this study is a retrospective study trying to find the predictive factors for medullary thyroid aggressiveness in terms of tumor metastasis and patients' survival. the predictive factors included in this study are central and lateral compartment lymph node metastases as well as distant metastasis up to 1 year postoperatively, while biochemical predictors (meaning ratios such as lymphocyte to monocyte ratio etc and cea and calcitonin drop levels) and histological predictors (such as nuclear atypia, amyloid, immunohistochemistry, desmoplasia) are included as secondary outcomes. in this study , patients \>18 years old that underwent surgery for medullary thyroid cancer (total thyroidectomy, completion thyroidectomy) +/- central/lateral neck dissection) will be enrolled.

Eligibility criteria:
inclusion criteria: * patients who underwent thyroidectomy for medullary thyroid cancer (total thyroidectomy, completion thyroidectomy) +/- central/lateral neck dissection exclusion criteria: * age \< 18 years
efficacy, safety, & tolerability of azd3480 patients with mild to moderate dementia of the alzheimer's type (ad)

Conditions: Alzheimer's Disease

Summary: alzheimer's disease is the most common form of dementia and is the fourth leading cause of death among people 65 years of age and older. the global prevalence of the disease will increase significantly as the population ages, unless preventative treatments can be identified and marketed. the present study seeks to evaluate azd3480 (tc-1734) compared to an approved medication (donepezil) shown to improve cognition and function in patients with alzheimer's disease.

this is a double blind, positive comparator, randomized, multicenter, parallel group study to assess the efficacy, safety, and tolerability of azd3480 as monotherapy in patients with mild to moderate dementia of the alzheimer's type (ad). approximately 300 subjects will be randomized and divided into 2 cohorts. actual randomization was 293 subjects.

Eligibility criteria:
inclusion criteria: 1. a clinical diagnosis of ad per nincds-adrda criteria; mild to moderate severity as defined by mini-mental state examination (mmse) scores of 12 to 22. 2. ad diagnosed at least 12 months prior to screening, and supported by brain imaging studies within 6 months prior to screening. 3. absence of vascular dementia both per airens criteria and as defined by modified hachinski ischemia score (his) of \</= 4. 4. presence of a caregiver with significant proportion of time in contact with subject and who will oversee administration of study drug during the trial 5. able to complete test assessments and to sign informed consent with the help of a caregiver if needed exclusion criteria: 1. diagnosis or presence of other dementing illnesses 2. use of mood stabilizers, antidepressants, anxiolytics, antipsychotics or hypnotics 3. treatment within 1 month prior to screening using cognition-affecting agents (e.g. cns stimulants) 4. tobacco user within 4 months prior to screening 5. use of smoking cessation therapy within 4 months prior to screening 6. history within past 6 months of alcohol abuse or illicit drug abuse 7. unable, even with caregiver assistance, to comply with study procedures in opinion of investigator 8. myocardial infarction within the 12 months prior to screening 9. hypothyroidism, vitamin b12 or folic acid deficiency 10. known systemic infection (hbv, hcv, hiv, tb) 11. vascular dementia per ninds-airens criteria and as defined by a modified hachinski ischemia score (his, appendix 4) score of \> 4 (i.e., vascular dementia is consistent with a modified his \> 4).

Keywords: alzheimer's disease ad dementia
genetic basis of primary immunodeficiencies

Conditions: Immunologic Deficiency Syndrome

Summary: the purpose of this study is to evaluate patients with primary immunodeficiency disorders to identify patients with mutations of the genes for the following proteins: jak3, stat1, stat4, interleukin-7, interleukin-7 receptor, interleukin-12 receptor subunits, and others. patients will undergo screening history, physical examination, and clinical laboratory evaluation at referring institutions and tissue samples, or cell lines will be sent to the nih. we will establish cell lines if necessary, prepare dna and rna for molecular genetic analysis and study cytokine signal transduction in patient cell lines.

the purpose of this study is to evaluate patients with primary immunodeficiency disorders to identify patients with mutations of the genes for the following proteins: jak3, stat1, stat4, interleukin-7, interleukin-7 receptor, interleukin-12 receptor subunits, and others. patients will undergo screening history, physical examination, and clinical laboratory evaluation at referring institutions and tissue samples, or cell lines will be sent to the nih. we will establish cell lines if necessary, prepare dna and rna for molecular genetic analysis and study cytokine signal transduction in patient cell lines.

Eligibility criteria:
* inclusion criteria: samples from patients with known or suspected primary immunodeficiencies, including those treated with stem cell transplants or gene correction therapy, and their families will be accepted worldwide primarily from tertiary care centers that treat patients with such immunodeficiencies. such patients will have documented evidence of either opportunistic infection, recurrent infection, or unusually severe responses to infectious agents that cause mild illness in unaffected individuals. in selected cases, at the discretion of the investigators, samples for testing will be obtained from consenting adult relatives of affected individuals. either patient-derived b cell lines or primary blood samples will be accepted although in some cases buccal swabs will also be accepted. blood samples may be obtained from unaffected children. additionally; patients with particularly interesting clinical presentations (e.g. adults with possible attenuated immunodeficiency) may be seen for outpatient visits at the nih clinical center for evaluation. infants with scid or other primary immunodeficiency will not be seen; their physicians will care them for and only clinical material will be sent on such patients. medically stable patients with mild to moderate immunodeficiency may be seen at the nih. we will encourage the participation of women and members of minority groups in this study. exclusion criteria: inability to provide informed consent. a presence of any medical condition that would, in the opinion of the investigators, confuse the interpretation of the study.

Keywords: cytokine stat jak il-12 mutation immunodeficiency
changes in glucose tolerance in patients with cirrhosis peri-liver transplant

Conditions: Cirrhosis, Liver; Diabetes Mellitus Risk; Transplant; Failure, Liver; Transplant-Related Disorder

Summary: the goal of this observational study is to establish risk factors for post-transplant in adult individuals with cirrhosis without diabetes undergoing liver transplant evaluation. the question being addressed is: can laboratory work, anthropometric tests, functional tests, imaging, and advanced measurements such as wrist actigraphy, continuous glucose monitoring, or oral glucose tolerance testing predict the development of diabetes after liver transplant? participants will be asked to periodically participate in wearing a continuous glucose monitor and wrist actigraph and obtain an oral glucose tolerance test both before and after liver transplant.

participants will be enrolled from the liver transplant clinic and will be given a continuous glucose monitor, a wrist actigraph, a home sleep apnea testing device, and a questionnaire packet to collect demographics, sleep quality, and physical activity information. they will be scheduled for an outpatient two-hour oral glucose tolerance test, which will use a frequently sampling protocol to allow for mathematical modeling of insulin secretion. they will undergo body composition measurements using a bio-electrical impedance analysis device. subjects will undergo these tests, excluding the home sleep apnea test, every three months until and through liver transplantation, after which they will restart the protocol at three months, or one month after post-transplant steroids are weaned to their lowest level. after they are one year post-transplant, they will no longer participate in continuous glucose monitoring or oral glucose tolerance testing, but their care will be followed electronically to assess outcomes up to five years post-transplant.

Eligibility criteria:
inclusion criteria: * patients presenting to liver transplant clinic with a diagnosis of cirrhosis. * age \>18 yrs. * ability to understand and sign written consent form, or have a legally-authorized representative or proxy who can be approached for consent exclusion criteria: * patients without consent * patients with implantable cardioverter defibrillator devices or automated implantable cardioverter defibrillator devices will be excluded from the bio-electrical impedance analysis portion of the measurements. * patients with unremovable electrical medical devices or devices that cannot turn off will be excluded from the bio-electrical impedance analysis measurements * pregnant patients * incarcerated patients * patients with a history of type 2 diabetes mellitus diagnosed \> 5 years ago will be excluded from the oral glucose tolerance test portion of the study

Keywords: cirrhosis post-transplant diabetes new-onset diabetes after transplant liver transplantation
cognitive stimulation and strength training in older adults with cognitive impairment

Conditions: Cognitive Impairment

Summary: this program focuses on integrating cognitive exercises and strength training for older adults experiencing mild cognitive impairment (mci). it aims to enhance cognitive functions such as memory, attention, and problem-solving skills through various stimulating activities. at the same time, it incorporates strength training exercises to improve muscle mass, balance, and overall physical mobility. by addressing both cognitive and physical aspects of health, the initiative seeks to provide comprehensive benefits that may lead to improved quality of life for older adults with mci. the research contributes valuable insights into the importance of holistic interventions in mitigating the effects of cognitive decline and promoting physical well-being in this vulnerable population.


Eligibility criteria:
inclusion criteria: * people over 60 years of age. * diagnosis of mild cognitive impairment (mci) confirmed by neuropsychological evaluation or by a health professional. * ability to participate in moderate physical activities and perform strength exercises with supervision. * willingness and ability to regularly attend sessions of the cognitive stimulation and physical training program. * signed informed consent authorization, indicating that they understand and accept the objectives and activities of the program. exclusion criteria: * diagnosis of moderate or severe dementia or other advanced cognitive impairment that prevents participation in the program. * severe or limiting physical conditions, such as heart disease, respiratory disease, or musculoskeletal injuries, that make it impossible to perform strength exercises. * psychiatric disorders (such as major depression or schizophrenia) or substance use that affect commitment or ability to follow the program activities. * participation in other cognitive stimulation or physical training programs or interventions in parallel, which may interfere with the evaluation of the effects of the program. * inability to understand and follow simple instructions, or lack of family or social support to attend the program if necessary.
melissa officinalis l. supplementation for emotional health and sleep disturbance

Conditions: Depression; Anxiety; Stress; Insomnia

Summary: this study is aimed to investigate if lemon balm extract supplementation is beneficial for the relief of stress, depression and anxiety in healthy adults.

lemon balm (botanical name: melissa officinalis l.) is a herbal plant belongs to the lamiaceae (mint) family, and currently of wide scientific interest as possible adjuvant for calming effect. lemon balm is one of the most popular and widely used medicinal herbs in central and southern europe, the mediterranean region, and west asia. the european scientific cooperative on phytotherapy (escop) recommends the use of lemon balm to relieve of mild symptoms of anxiety, including mental stress, restlessness, and irritability. historically, lemon balm has been widely used in asian traditional medicine as a sedative to treat many psychiatric disorders, such as stress, depression, anxiety, and insomnia. lemon balm has shown anti-depressant, anxiolytic, and anti-insomnia effects both in human clinical trials and in animal model studies.

Eligibility criteria:
inclusion criteria: * healthy individuals, aged 18 - 65 years * individuals suffering from moderate degree of depression, anxiety, and stress with dass scores ≥14, ≥10, and ≥19, respectively, or individual with sleep problems with pittsburgh sleep quality index (psqi) score ≥5. * willing to participate in the study exclusion criteria: * current use of prescribed medication or supplements for neuropsychiatric and sleep disorders * known history of neuropsychiatric or sleep disorders * current use or history of illicit substances misuse * history of any allergic reactions to ingredients of the lemon balm extract * hypertension (systolic blood pressure ≥ 140 mmhg or diastolic blood pressure ≥ 90, or other cardiovascular disease * hyperthyroidism or diabetes mellitus or cancer * use of blood thinners like coumadin (warfarin) or plavix (clopidogrel), glaucoma medications like travatan (travoprost), chemotherapy drugs like tamoxifen and camptosar (irinotecan) * severe medical problem, which in the opinion of the investigator would pose a safety risk to the subject
mass - maastricht sarcopenia study

Conditions: Sarcopenia

Summary: the objective of this cross-sectional study is to obtain insight in the characteristics (nutritional status and level of physical activity) of sarcopenic compared to non-sarcopenic community-dwelling older people. there is one measurement moment and measurements will take place at the participant's home.

* characterization of sarcopenic older people (demographics, nutritional status, level of physical activity) * prevalence rates of sarcopenia in community-dwelling older people in the netherlands * insight in differences and/or overlap between sarcopenia versus frailty * insight in the impact of sarcopenia on economic outcomes

Eligibility criteria:
inclusion criteria: * ≥ 65 years old * have given informed consent * understand dutch language * able to perform a walk test exclusion criteria: * older people living in a nursing home * older people with active rheumatoid arthritis, post stroke status with evident lingering symptoms (paralysis, loss of motor functions), diseases of the nervous system like parkinson and ms, active angina pectoris, dementia * older people in a wheelchair, with icd or pacemaker
multiple burrhole therapy with erythropoietin for unstable moyamoya

Conditions: Ischemic Attack; Ischemic Stroke; Moyamoya Disease; Burr Hole; Angiogenesis

Summary: in this study, the investigators aim to evaluate the indirect revascularization outcomes of a new combination therapy of multiple burrhole procedure with promotion of arteriogenesis by intravenous (iv) erythropoietin (epo) pretreatment on moyamoya patients with acute neurological presentation, and outline the clinical and vascular factors associated with revascularization through the burrholes.

this is a investigator led, single-center, single arm, interventional trial in prospective moyamoya disease (mmd) and moyamoya syndrome (mms) registry. mmd or mms patients with acute neurological presentation such as ischemic stroke or transient ischemic attack are eligible. after inclusion, initial evaluation including transfemoral angiography is performed. a 3 day pre-procedure iv erythropoietin (120000 international units\[iu\] #3) is given for promotion of arteriogenesis, than multiple burrhole procedure is performed. arteriogenesis is evaluated by 6 month transfemoral angiography.

Eligibility criteria:
inclusion criteria: * age ≥16 years * acute neurological presentation with recurrent transient ischemic attacks (tia) or cerebral infarction within 30 days of symptom onset * angiographic findings compatible with the diagnostic criteria for mmd or mms (unilateral findings, bilateral distal internal carotid artery involvement without moyamoya vessels, or presence of other causative factors) * significant decrease in basal perfusion and reservoir capacity on brain perfusion ct or brain single photon emission computed tomography with acetazolamide (diamox®) challenge (d-spect) exclusion criteria: * definite presence of transdural collateral flow on cerebral angiography. * sufficient perfusion status via willisian, leptomeningeal, or other collateral systems, as evaluated by multimodal imaging methods. * \> 30 days after symptom onset
acupressure applied after cesarean section on postpartum pain

Conditions: Postpartum Disorder; Cesarean Section Complications

Summary: pressure applied according to the principles of acupressure limits the pain limit, reduces the secretion of endorphins, which is a neurochemical, reduces the tension in the muscles, reduces the amount of oxygen in the blood flow, and finally provides duration and relaxation. acupressure application is becoming more and more common nowadays because it is a noninvasive, safe, easy-to-apply and effective method without side effects. it seems that there is a limit to the study in which group acupressure applications in the literature are examined together on pain and comfort after cesarean section. in these basic points, the expectations of achieving postpartum pain and postpartum comfort of acupressure applied after cesarean delivery in this study. the circle of the research; there will be women who will have repeated cesarean section in a private obstetrics clinic in famagusta. women will be separated from two groups, one group will continue acupressure and the other group will do routine care. visual analog scale and end-of-birth comfort procedure will be applied to women before and after the application.

pressure applied according to the principles of acupressure limits the pain limit, reduces the secretion of endorphins, which is a neurochemical, reduces the tension in the muscles, reduces the amount of oxygen in the blood flow, and finally provides duration and relaxation. acupressure application is becoming more and more common nowadays because it is a noninvasive, safe, easy-to-apply and effective method without side effects. it seems that there is a limit to the study in which group acupressure applications in the literature are examined together on pain and comfort after cesarean section. in these basic points, the expectations of achieving postpartum pain and postpartum comfort of acupressure applied after cesarean delivery in this study. the circle of the research; there will be women who will have repeated cesarean section in a private obstetrics clinic in famagusta. women will be separated from two groups, one group will continue acupressure and the other group will do routine care. visual analog scale and end-of-birth comfort procedure will be applied to women before and after the application.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the research, * be between the ages of 18-49, * to give birth by cesarean section between 37-40 weeks, * having a healthy and live birth at the end of a single pregnancy, * receiving spinal anesthesia * being able to read and write turkish and be open to communication. exclusion criteria: * absence of pain in the 2nd hour postpartum * having a cesarean delivery after a risky pregnancy, * having a chronic illness * having severe systemic disease * not receiving spinal anesthesia * having a body mass index over 25, * have previous acupressure experience.

Keywords: cesarean section acupressure postpartum pain postpartum comfort
procalcitonin use in pneumonia patients in the critical care setting

Conditions: Pneumonia

Summary: the goal of the study is to determine the impact of procalcitonin (pct)-guided therapy on duration of antibiotic therapy in critical care unit (ccu) patients with suspected pneumonia at mayo clinic health system eau claire.


Eligibility criteria:
inclusion criteria: * 18 years old * admitted to critical care unit * placed on pneumonia protocol exclusion criteria: * patients who received outpatient antibiotic therapy within previous 21 days

Keywords: procalcitonin antimicrobial stewardship pneumonia